DEUTSCHE BANK AG\ - AIMMUNE THERAPEUTICS INC ownership

AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 129 filers reported holding AIMMUNE THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.77 and the average weighting 0.9%.

Quarter-by-quarter ownership
DEUTSCHE BANK AG\ ownership history of AIMMUNE THERAPEUTICS INC
ValueSharesWeighting
Q3 2020$2,385,000
-14.0%
69,244
-58.3%
0.00%0.0%
Q2 2020$2,773,000
-52.5%
165,999
-59.0%
0.00%
-60.0%
Q1 2020$5,839,000
-47.5%
404,967
+21.9%
0.01%
-28.6%
Q4 2019$11,115,000
+172.4%
332,180
+70.4%
0.01%
+133.3%
Q3 2019$4,080,000
-8.8%
194,956
-9.3%
0.00%0.0%
Q2 2019$4,474,000
+32.4%
215,024
+42.1%
0.00%
+50.0%
Q1 2019$3,379,000
+48.1%
151,270
+58.6%
0.00%0.0%
Q4 2018$2,281,000
-83.9%
95,375
-81.6%
0.00%
-50.0%
Q3 2018$14,137,000
+12.8%
518,288
+11.2%
0.00%0.0%
Q2 2018$12,528,000
+25.7%
465,928
+48.7%
0.00%
-20.0%
Q1 2018$9,968,000
+19.9%
313,269
+42.5%
0.01%0.0%
Q4 2017$8,311,000
+47.2%
219,817
-3.5%
0.01%
+25.0%
Q3 2017$5,647,000
+141.7%
227,880
+100.4%
0.00%
+100.0%
Q2 2017$2,336,000
+39.4%
113,694
+47.2%
0.00%
+100.0%
Q1 2017$1,676,000
-21.4%
77,222
-25.9%
0.00%
-50.0%
Q4 2016$2,131,000
+73.7%
104,283
+27.3%
0.00%
+100.0%
Q3 2016$1,227,000
+51.7%
81,937
+9.4%
0.00%0.0%
Q2 2016$809,000
+937.2%
74,895
+1193.5%
0.00%
Q1 2016$78,000
+56.0%
5,790
+108.7%
0.00%
Q4 2015$50,000
-35.1%
2,774
-9.8%
0.00%
Q3 2015$77,0003,0740.00%
Other shareholders
AIMMUNE THERAPEUTICS INC shareholders Q2 2019
NameSharesValueWeighting ↓
Foresite Capital Management II, LLC 3,300,797$90,046,00033.32%
Aisling Capital LLC 1,990,000$54,287,00011.73%
Foresite Capital Management III, LLC 801,240$21,858,0004.82%
PACIFIC VIEW ASSET MANAGEMENT, LLC 189,857$5,181,0004.12%
AlpInvest Partners B.V. 38,943$1,062,0002.27%
Eventide Asset Management 1,739,000$47,440,0001.74%
Palo Alto Investors LP 1,381,759$37,694,0001.52%
Sofinnova Investments, Inc. 222,295$6,064,0000.54%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 553,000$15,086,0000.54%
EMERALD ADVISERS, LLC 486,666$13,276,0000.49%
View complete list of AIMMUNE THERAPEUTICS INC shareholders